指南与共识复苏、休克与脓毒症心脑血管急症重症综合管理与镇静镇痛

口服抗凝药患者严重出血的管理:EMCREG国际多学科严重出血共识专家组会议论文集(2018年10月20日)

Management of Severe Bleeding in Patients Treated With Oral Anticoagulants: Proceedings Monograph From the Emergency Medicine Cardiac Research and Education Group-International Multidisciplinary Severe Bleeding Consensus Panel October 20, 2018.
指南 / 共识 · Crit Pathw Cardiol · 2019-01-01
一句话结论口服抗凝药相关严重出血应首先替换血液成分并逆转抗凝,EMCREG国际共识提供了面向急诊与ICU的处置流程。

本文为2018年10月20日在美国奥兰多召开的EMCREG国际多学科严重出血共识专家组会议论文集,聚焦口服抗凝药(华法林、凝血酶抑制剂达比加群、Xa因子抑制剂阿哌沙班与利伐沙班)治疗患者的严重出血管理。文中强调,对因口服抗凝药出现严重、不可控出血而就诊于急诊科、ICU或手术室的患者,快速可控止血是挽救生命的关键;替换红细胞、血小板及凝血因子是关键的初始治疗,同时必须逆转抗凝状态。华法林患者输注维生素K以启动维生素K依赖性凝血蛋白Ⅱ、Ⅶ、Ⅸ、Ⅹ及抗血栓蛋白C、蛋白S的合成,4因子凝血酶原复合物可实时减缓出血;达比加群患者可用idarucizumab逆转;2018年5月美国FDA批准andexanet alfa用于逆转阿哌沙班和利伐沙班所致大出血。文中还讨论了有效治疗后尽早、安全地恢复口服抗凝以预防血栓并发症,并提供了国际严重出血共识专家组的处置流程图。

要点

  • 口服抗凝药相关严重、不可控出血患者就诊急诊科、ICU或手术室时,快速可控止血是挽救生命的关键。
  • 替换红细胞、血小板及凝血因子是此类患者关键的初始治疗,同时必须逆转抗凝状态。
  • 华法林相关出血:输注维生素K启动维生素K依赖性凝血蛋白Ⅱ、Ⅶ、Ⅸ、Ⅹ及蛋白C、蛋白S合成;4因子凝血酶原复合物提供实时减缓出血能力。
  • 达比加群相关出血:使用高特异性抗体衍生的idarucizumab已被证实可逆转低凝状态、恢复血凝。
  • 2018年5月美国FDA批准andexanet alfa用于逆转阿哌沙班和利伐沙班所致大出血;此前Xa因子抑制剂严重出血通常替换血液成分并使用4因子凝血酶原复合物,无此药时用新鲜冰冻血浆。

适用人群与场景

  • 接受口服抗凝药(华法林、凝血酶抑制剂达比加群、Xa因子抑制剂阿哌沙班与利伐沙班)治疗并出现严重出血的患者。
  • 就诊场景为急诊科、重症监护病房或手术室。

处置流程与药物剂量

  • 对口服抗凝药相关严重出血患者,替换血液成分(红细胞、血小板、凝血因子)是关键的最初治疗,同时需逆转抗凝状态。
  • 华法林相关出血:输注维生素K以启动维生素K依赖性凝血蛋白Ⅱ、Ⅶ、Ⅸ、Ⅹ及抗血栓蛋白C、蛋白S的合成。
  • 华法林相关出血:使用4因子凝血酶原复合物补充凝血因子(含因子Ⅱ、Ⅶ、Ⅸ、Ⅹ及治疗有效浓度的蛋白C、蛋白S),提供实时减缓出血的能力。
  • 达比加群相关出血:使用高特异性、抗体衍生的idarucizumab逆转低凝状态以恢复血凝。
  • 阿哌沙班或利伐沙班相关大出血:2018年5月美国FDA批准andexanet alfa用于逆转。
  • Xa因子抑制剂严重出血且无andexanet alfa时:通常替换丢失的血液成分(红细胞、血小板、凝血因子)并使用4因子凝血酶原复合物,若无则使用新鲜冰冻血浆。
  • 严重出血经有效治疗后可恢复口服抗凝:应尽早且在安全的前提下恢复抗凝状态,以预防血栓并发症。

红旗征与不能漏的情况

  • 口服抗凝药治疗患者出现严重、不可控出血,需快速可控止血以挽救生命。

研究设计与关键结果

  • 本文为2018年10月20日EMCREG国际多学科严重出血共识专家组会议论文集,综合急诊心血管监护、院前急救、急诊运营、血液学、医院医学、神经重症、心血管重症、心脏电生理、心脏病学、创伤与急症外科及药学等多学科专家的意见。
  • 文中提供了EMCREG国际严重出血共识专家组针对危及生命的口服抗凝药相关出血的处理流程图,可供急诊科或重症监护病房等治疗区域放大使用。

证据类型、等级与局限

  • 证据类型:多学科共识专家组会议论文集(指南/共识)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对口服抗凝药相关严重出血患者,床旁应同时启动血液成分替换与抗凝逆转,而非仅观察等待。
  • 华法林相关严重出血时,维生素K与4因子凝血酶原复合物联合用于启动凝血蛋白合成并实时减缓出血;达比加群相关出血使用idarucizumab;阿哌沙班或利伐沙班相关大出血可考虑andexanet alfa(2018年5月获美国FDA批准)。
  • 有效止血后应尽早且在安全前提下恢复口服抗凝,以预防血栓并发症。
  • 共识专家组提供了可放大张贴于急诊科或重症监护病房的严重出血处置流程图。

指南或共识出处

  • Management of Severe Bleeding in Patients Treated With Oral Anticoagulants: Proceedings Monograph From the Emergency Medicine Cardiac Research and Education Group-International Multidisciplinary Severe Bleeding Consensus Panel October 20, 2018(EMCREG国际多学科严重出血共识专家组,2018年)

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

In this Emergency Medicine Cardiac Research and Education Group (EMCREG)-International Proceedings Monograph from the October 20, 2018, EMCREG-International Multidisciplinary Consensus Panel on Management of Severe Bleeding in Patients Treated With Oral Anticoagulants held in Orlando, FL, you will find a detailed discussion regarding the treatment of patients requiring anticoagulation and the reversal of anticoagulation for patients with severe bleeding. For emergency physicians, critical care physicians, hospitalists, cardiologists, internists, surgeons, and family physicians, the current approach and disease indications for treatment with anticoagulants such as coumadin, factor IIa, and factor Xa inhibitors are particularly relevant. When a patient treated with anticoagulants presents to the emergency department, intensive care unit, or operating room with severe, uncontrollable bleeding, achieving rapid, controlled hemostasis is critically important to save the patient's life. This EMCREG-International Proceedings Monograph contains multiple sections reflecting critical input from experts in Emergency Cardiovascular Care, Prehospital Emergency Medical Services, Emergency Medicine Operations, Hematology, Hospital Medicine, Neurocritical Care, Cardiovascular Critical Care, Cardiac Electrophysiology, Cardiology, Trauma and Acute Care Surgery, and Pharmacy. The first section provides a description of the current indications for the treatment of patients using oral anticoagulants including coumadin, the factor IIa (thrombin) inhibitor dabigatran, and factor Xa inhibitors such as apixaban and rivaroxaban. In the remaining sections, the treatment of patients presenting to the hospital with major bleeding becomes the focus. The replacement of blood components including red blood cells, platelets, and clotting factors is the critically important initial treatment for these individuals. Reversing the anticoagulated state is also necessary. For patients treated with coumadin, infusion of vitamin K helps to initiate the process of protein synthesis for the vitamin K-dependent coagulation proteins II, VII, IX, and X and the antithrombotic protein C and protein S. Repletion of clotting factors for the patient with 4-factor prothrombin complex concentrate, which includes factors II (prothrombin), VII, IX, and X and therapeutically effective concentrations of the regulatory proteins (protein C and S), provides real-time ability to slow bleeding. For patients treated with the thrombin inhibitor dabigatran, treatment using the highly specific, antibody-derived idarucizumab has been demonstrated to reverse the hypocoagulable state of the patient to allow blood clotting. In May 2018, andexanet alfa was approved by the US Food and Drug Administration to reverse the factor Xa anticoagulants apixaban and rivaroxaban in patients with major bleeding. Before the availability of this highly specific agent, therapy for patients treated with factor Xa inhibitors presenting with severe bleeding usually included replacement of lost blood components including red blood cells, platelets, and clotting factors and 4-factor prothrombin complex concentrate, or if not available, fresh frozen plasma. The evaluation and treatment of the patient with severe bleeding as a complication of oral anticoagulant therapy are discussed from the viewpoint of the emergency physician, neurocritical and cardiovascular critical care intensivist, hematologist, trauma and acute care surgeon, hospitalist, cardiologist, electrophysiologist, and pharmacist in an approach we hope that the reader will find extremely practical and clinically useful. The clinician learner will also find the discussion of the resumption of oral anticoagulation for the patient with severe bleeding after effective treatment important because returning the patient to an anticoagulated state as soon as feasible and safe prevents thrombotic complications. Finally, an EMCREG-International Severe Bleeding Consensus Panel algorithm for the approach to management of patients with life-threatening oral anticoagulant-associated bleeding is provided for the clinician and can be expanded in size for use in a treatment area such as the emergency department or critical care unit.

来源:Crit Pathw Cardiol,查看原文。版权归原作者所有。

参考来源

  1. Gibler WB, Racadio JM, Hirsch AL, et al. Management of Severe Bleeding in Patients Treated With Oral Anticoagulants: Proceedings Monograph From the Emergency Medicine Cardiac Research and Education Group-International Multidisciplinary Severe Bleeding Consensus Panel October 20, 2018. Crit Pathw Cardiol. 2019. PMID: 31348075. doi:10.1097/HPC.0000000000000181

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。